Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 1 Interventional

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

NCT02680561
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 17, 2026, 8:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

NCT07413666
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
ORX489 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CTLA4-IgG4m (RG2077), Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Vabametkib, Lazertinib
Drug
Lead sponsor
Abion Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

NCT01493596
View directory record Official record
Conditions
Cocaine Dependency
Interventions
CPP-115, Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

NCT01766154
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Results available

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

NCT01937260
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Anaheim, California • Irvine, California • Ocala, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer

NCT01417182
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

NCT02013388
View directory record Official record
Conditions
Healthy
Interventions
N91115, Placebo, Placebo-Day 1 only
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Japanese Pharmacokinetic Bridging Study for CC-93538

NCT04096105
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

NCT03508570
View directory record Official record
Conditions
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Peritoneal Carcinomatosis, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Malignant Female Reproductive System Neoplasm, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacokinetic Study
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

NCT04331288
View directory record Official record
Conditions
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Interventions
PT150, Beverage
Drug · Other
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

NCT05280054
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
AV-101, Probenecid
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

NCT01568749
View directory record Official record
Conditions
Analgesia
Interventions
Paracetamol, Paracetamol formulation 1, Paracetamol Formulation 2, Paracetamol formulation 3, Paracetamol formulation 4
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 2 Interventional

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

NCT00240643
View directory record Official record
Conditions
Fibrillation, Atrial, Atrial Fibrillation
Interventions
SB424323
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Mobile, Alabama • Troy, Michigan • Akron, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

NCT07543276
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 8:05 PM EDT
Not listed Phase 1Phase 2 Interventional

IMX-110 in Patients With Advanced Solid Tumors

NCT03382340
View directory record Official record
Conditions
Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer, Ovarian Cancer
Interventions
Imx-110
Drug
Lead sponsor
Immix Biopharma Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 17, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia

NCT00001689
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Leukemia
Interventions
Vincristine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 8:05 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Intravaginal KB15A

NCT07222020
View directory record Official record
Conditions
Healthy Subjects
Interventions
KB15A Vaginal Film, Placebo Vaginal Film
Drug
Lead sponsor
ZabBio Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 8:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 8:05 PM EDT